BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia. Blood Adv. 2023 Feb 10.
View in:
PubMed
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy. Clin Cancer Res. 2022 12 15; 28(24):5455-5468.
View in:
PubMed
Collateral deletion of the mitochondrial AAA+ ATPase ATAD1 sensitizes cancer cells to proteasome dysfunction. Elife. 2022 11 21; 11.
View in:
PubMed
Precision medicine in AML: Function plus -omics is better than either alone. Cancer Cell. 2022 08 08; 40(8):804-806.
View in:
PubMed
Challenges and opportunities for physician-scientists in advancing cancer research. Trends Cancer. 2022 08; 8(8):615-619.
View in:
PubMed
Author Correction: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma. Leukemia. 2022 Jun; 36(6):1700.
View in:
PubMed
Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression. Clin Cancer Res. 2022 06 01; 28(11):2397-2408.
View in:
PubMed
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia. Nat Cancer. 2022 05; 3(5):595-613.
View in:
PubMed
Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. Cell. 2022 04 28; 185(9):1521-1538.e18.
View in:
PubMed
JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. Leukemia. 2022 06; 36(6):1499-1507.
View in:
PubMed
Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther. 2022 Apr 01; 7(1):110.
View in:
PubMed
Apoptosis: Directly Targeted at Last. J Clin Oncol. 2022 05 20; 40(15):1693-1695.
View in:
PubMed
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther. 2022 02 21; 7(1):51.
View in:
PubMed
Functional Precision Medicine: Putting Drugs on Patient Cancer Cells and Seeing What Happens. Cancer Discov. 2022 02; 12(2):290-292.
View in:
PubMed
Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma. Leukemia. 2022 04; 36(4):1088-1101.
View in:
PubMed
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. Blood Adv. 2021 12 28; 5(24):5536-5545.
View in:
PubMed
Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer Cell. 2022 01 10; 40(1):26-35.
View in:
PubMed
Control of lysosomal-mediated cell death by the pH-dependent calcium channel RECS1. Sci Adv. 2021 Nov 12; 7(46):eabe5469.
View in:
PubMed
In Conversation with Tony Letai. FEBS J. 2021 11; 288(21):6087-6094.
View in:
PubMed
Activation of Notch and Myc Signaling via B-cell-Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia. Cancer Res. 2021 12 15; 81(24):6117-6130.
View in:
PubMed
An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML. Cancer Discov. 2022 02; 12(2):432-449.
View in:
PubMed
BH3-only proteins are part of a regulatory network that control the sustained signalling of the unfolded protein response sensor IRE1a. EMBO J. 2021 Sep 15; 40(18):e109146.
View in:
PubMed
Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer. Breast Cancer Res. 2021 08 05; 23(1):83.
View in:
PubMed
Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer. Cell Death Dis. 2021 07 27; 12(8):741.
View in:
PubMed
Cell Line-Specific Network Models of ER+ Breast Cancer Identify Potential PI3Ka Inhibitor Resistance Mechanisms and Drug Combinations. Cancer Res. 2021 09 01; 81(17):4603-4617.
View in:
PubMed
Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment. Nat Cancer. 2021 07; 2(7):758-772.
View in:
PubMed
ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins. Cells. 2021 07 02; 10(7).
View in:
PubMed
Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening. Cancer Discov. 2021 10; 11(10):2544-2563.
View in:
PubMed
Death in the Fas, ELANE. Cell. 2021 06 10; 184(12):3081-3083.
View in:
PubMed
Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics. Sci Signal. 2021 06 08; 14(686).
View in:
PubMed
Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration. Proc Natl Acad Sci U S A. 2021 06 08; 118(23).
View in:
PubMed
Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma. Blood Adv. 2021 05 11; 5(9):2391-2402.
View in:
PubMed
Apoptotic Blocks in Primary Non-Hodgkin B Cell Lymphomas Identified by BH3 Profiling. Cancers (Basel). 2021 Feb 28; 13(5).
View in:
PubMed
Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer. Sci Adv. 2021 01; 7(3).
View in:
PubMed
An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities. Blood Cancer Discov. 2021 01; 2(1):70-91.
View in:
PubMed
Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer. Breast Cancer Res. 2020 11 30; 22(1):132.
View in:
PubMed
Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Cancer Cell. 2020 12 14; 38(6):872-890.e6.
View in:
PubMed
Aneuploidy increases resistance to chemotherapeutics by antagonizing cell division. Proc Natl Acad Sci U S A. 2020 12 01; 117(48):30566-30576.
View in:
PubMed
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. Am J Hematol. 2021 02 01; 96(2):208-217.
View in:
PubMed
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. Nat Cancer. 2021 01; 2(1):34-48.
View in:
PubMed
Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes. Blood Adv. 2020 10 27; 4(20):5226-5231.
View in:
PubMed
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020 08 13; 383(7):617-629.
View in:
PubMed
Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition. Cancer Discov. 2020 10; 10(10):1500-1513.
View in:
PubMed
High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors. Sci Signal. 2020 06 16; 13(636).
View in:
PubMed
Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy. Am J Hematol. 2020 03; 95(3):245-250.
View in:
PubMed
Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies. Nat Commun. 2019 11 14; 10(1):5157.
View in:
PubMed
DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. J Clin Invest. 2019 11 01; 129(11):5005-5019.
View in:
PubMed
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell. 2019 10 14; 36(4):369-384.e13.
View in:
PubMed
Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer. Mol Cancer Res. 2019 11; 17(11):2281-2293.
View in:
PubMed
Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumor. JCI Insight. 2019 08 08; 4(15).
View in:
PubMed
MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. Nat Commun. 2019 08 02; 10(1):3485.
View in:
PubMed
Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling. Cell Death Dis. 2019 07 29; 10(8):571.
View in:
PubMed
BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics. Cell Death Differ. 2020 03; 27(3):999-1007.
View in:
PubMed
Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs. Blood. 2019 07 11; 134(2):160-170.
View in:
PubMed
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019 03; 20(3):175-193.
View in:
PubMed
MCL1 and DEDD Promote Urothelial Carcinoma Progression. Mol Cancer Res. 2019 06; 17(6):1294-1304.
View in:
PubMed
Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas. Blood. 2019 02 07; 133(6):566-575.
View in:
PubMed
PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. J Exp Med. 2018 12 03; 215(12):3094-3114.
View in:
PubMed
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019 01 03; 133(1):7-17.
View in:
PubMed
Targeted inhibition of PI3Ka/d is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. Blood. 2019 01 03; 133(1):70-80.
View in:
PubMed
Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight. 2018 10 04; 3(19).
View in:
PubMed
BCL-2 inhibition in AML: an unexpected bonus? Blood. 2018 09 06; 132(10):1007-1012.
View in:
PubMed
Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance. EMBO Rep. 2018 09; 19(9).
View in:
PubMed
PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. Blood. 2018 09 13; 132(11):1095-1105.
View in:
PubMed
Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy. BMC Gastroenterol. 2018 Jun 22; 18(1):94.
View in:
PubMed
Statins enhance efficacy of venetoclax in blood cancers. Sci Transl Med. 2018 06 13; 10(445).
View in:
PubMed
Targeting B-Cell Lymphoma 2: A Lethal Shortcut in Del(17p) Chronic Lymphocytic Leukemia. J Clin Oncol. 2018 07 01; 36(19):1991-1993.
View in:
PubMed
Diminished apoptotic priming and ATM signalling confer a survival advantage onto aged haematopoietic stem cells in response to DNA damage. Nat Cell Biol. 2018 04; 20(4):413-421.
View in:
PubMed
MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. Cancer Discov. 2018 04; 8(4):478-497.
View in:
PubMed
Iterative optimization yields Mcl-1-targeting stapled peptides with selective cytotoxicity to Mcl-1-dependent cancer cells. Proc Natl Acad Sci U S A. 2018 01 30; 115(5):E886-E895.
View in:
PubMed
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018 02; 19(2):216-228.
View in:
PubMed
ER Stress Signaling Promotes the Survival of Cancer "Persister Cells" Tolerant to EGFR Tyrosine Kinase Inhibitors. Cancer Res. 2018 02 15; 78(4):1044-1057.
View in:
PubMed
Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis. Sci Transl Med. 2017 Dec 13; 9(420).
View in:
PubMed
Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax. Cancer Discov. 2017 12; 7(12):1376-1393.
View in:
PubMed
Overcoming mutational complexity in acute myeloid leukemia by inhibition of critical pathways. Sci Transl Med. 2017 Oct 25; 9(413).
View in:
PubMed
BCL-XL directly modulates RAS signalling to favour cancer cell stemness. Nat Commun. 2017 10 24; 8(1):1123.
View in:
PubMed
Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma. Nat Med. 2017 Nov; 23(11):1342-1351.
View in:
PubMed
Inhibition of USP10 induces degradation of oncogenic FLT3. Nat Chem Biol. 2017 Dec; 13(12):1207-1215.
View in:
PubMed
Functional precision cancer medicine-moving beyond pure genomics. Nat Med. 2017 Sep 08; 23(9):1028-1035.
View in:
PubMed
Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1. Elife. 2017 06 08; 6.
View in:
PubMed
Synergistic interactions with PI3K inhibition that induce apoptosis. Elife. 2017 05 31; 6.
View in:
PubMed
Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection. Elife. 2017 04 20; 6.
View in:
PubMed
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. Nature. 2017 03 16; 543(7645):428-432.
View in:
PubMed
Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells. Oncotarget. 2017 Mar 07; 8(10):16220-16232.
View in:
PubMed
Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia. 2017 10; 31(10):2075-2084.
View in:
PubMed
Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics. Cancer Cell. 2017 01 09; 31(1):142-156.
View in:
PubMed
Tight Sequestration of BH3 Proteins by BCL-xL at Subcellular Membranes Contributes to Apoptotic Resistance. Cell Rep. 2016 12 20; 17(12):3347-3358.
View in:
PubMed
Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors. FEBS Lett. 2017 Jan; 591(1):240-251.
View in:
PubMed
Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Cancer Discov. 2017 02; 7(2):156-164.
View in:
PubMed
S63845, an MCL-1 Selective BH3 Mimetic: Another Arrow in Our Quiver. Cancer Cell. 2016 Dec 12; 30(6):834-835.
View in:
PubMed
Genomic evolution and chemoresistance in germ-cell tumours. Nature. 2016 11 30; 540(7631):114-118.
View in:
PubMed
To Prime, or Not to Prime: That Is the Question. Cold Spring Harb Symp Quant Biol. 2016; 81:131-140.
View in:
PubMed
Cristae remodeling causes acidification detected by integrated graphene sensor during mitochondrial outer membrane permeabilization. Sci Rep. 2016 10 27; 6:35907.
View in:
PubMed
Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise. FEBS J. 2016 10; 283(19):3523-3533.
View in:
PubMed
Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Res. 2016 11 15; 76(22):6495-6506.
View in:
PubMed
Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia. J Clin Invest. 2016 10 03; 126(10):3827-3836.
View in:
PubMed
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discov. 2016 10; 6(10):1106-1117.
View in:
PubMed
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183.
View in:
PubMed
iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry. Biol Chem. 2016 07 01; 397(7):671-8.
View in:
PubMed
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016 05 20; 7:11589.
View in:
PubMed
BOK: Oddball of the BCL-2 Family. Trends Cell Biol. 2016 06; 26(6):389-390.
View in:
PubMed
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016 06 23; 127(25):3215-24.
View in:
PubMed
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586.
View in:
PubMed
Dynamic BH3 profiling-poking cancer cells with a stick. Mol Cell Oncol. 2016 May; 3(3):e1040144.
View in:
PubMed
Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines. Oncotarget. 2016 Mar 08; 7(10):11500-11.
View in:
PubMed
Mitochondria-Judges and Executioners of Cell Death Sentences. Mol Cell. 2016 Mar 03; 61(5):695-704.
View in:
PubMed
Rapid Optimization of Mcl-1 Inhibitors using Stapled Peptide Libraries Including Non-Natural Side Chains. ACS Chem Biol. 2016 05 20; 11(5):1238-44.
View in:
PubMed
MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Rep. 2015 Dec 29; 13(12):2715-27.
View in:
PubMed
Cell Death and Cancer Therapy: Don't Forget to Kill the Cancer Cell! Clin Cancer Res. 2015 Nov 15; 21(22):5015-20.
View in:
PubMed
Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer. 2015 Dec; 15(12):747-56.
View in:
PubMed
Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice. Leukemia. 2016 Jan; 30(1):190-9.
View in:
PubMed
Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma. Blood. 2015 Sep 24; 126(13):1555-64.
View in:
PubMed
BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia. 2016 Mar; 30(3):761-4.
View in:
PubMed
Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13; 28(1):29-41.
View in:
PubMed
Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 2015 Feb 26; 160(5):977-989.
View in:
PubMed
RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis. Sci Signal. 2014 Dec 23; 7(357):ra122.
View in:
PubMed
Potent and specific peptide inhibitors of human pro-survival protein Bcl-xL. J Mol Biol. 2015 Mar 27; 427(6 Pt B):1241-1253.
View in:
PubMed
Bcl-xL controls a switch between cell death modes during mitotic arrest. Cell Death Dis. 2014; 5:e1429.
View in:
PubMed
Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells. ACS Chem Biol. 2014 Sep 19; 9(9):1962-8.
View in:
PubMed
Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2014 Sep 01; 20(17):4520-31.
View in:
PubMed
Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014 Sep; 4(9):1074-87.
View in:
PubMed
Bcl-xL controls a switch between cell death modes during mitotic arrest. Cell Death Dis. 2014 Jun 12; 5:e1291.
View in:
PubMed
APC(Cdc20) suppresses apoptosis through targeting Bim for ubiquitination and destruction. Dev Cell. 2014 May 27; 29(4):377-91.
View in:
PubMed
Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014 Sep; 99(9):1499-508.
View in:
PubMed
Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis. Apoptosis. 2014 Apr; 19(4):629-42.
View in:
PubMed
Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells. Cell Death Differ. 2014 Jul; 21(7):1170-7.
View in:
PubMed
Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. Cancer Res. 2014 Jun 01; 74(11):3146-56.
View in:
PubMed
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014 Mar; 4(3):362-75.
View in:
PubMed
BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response. Mol Cell. 2013 Sep 26; 51(6):751-65.
View in:
PubMed
Mitochondria: gatekeepers of response to chemotherapy. Trends Cell Biol. 2013 Dec; 23(12):612-9.
View in:
PubMed
High mitochondrial priming sensitizes hESCs to DNA-damage-induced apoptosis. Cell Stem Cell. 2013 Oct 03; 13(4):483-91.
View in:
PubMed
Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. Leuk Lymphoma. 2013 Aug; 54(8):1823-5.
View in:
PubMed
p53 regulates a non-apoptotic death induced by ROS. Cell Death Differ. 2013 Nov; 20(11):1465-74.
View in:
PubMed
BH3 profiling in whole cells by fluorimeter or FACS. Methods. 2013 Jun 01; 61(2):156-64.
View in:
PubMed
BCL-2 inhibition: stemming the tide of myeloid malignancies. Cell Stem Cell. 2013 Mar 07; 12(3):269-70.
View in:
PubMed
ABT-199: taking dead aim at BCL-2. Cancer Cell. 2013 Feb 11; 23(2):139-41.
View in:
PubMed
KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol. 2013 Apr; 161(1):117-27.
View in:
PubMed
Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer. Breast Cancer Res. 2013; 15(5):317.
View in:
PubMed
Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell. 2012 Oct 12; 151(2):344-55.
View in:
PubMed
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov. 2012 Oct; 2(10):934-47.
View in:
PubMed
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood. 2012 Oct 25; 120(17):3501-9.
View in:
PubMed
BCL2 suppresses PARP1 function and nonapoptotic cell death. Cancer Res. 2012 Aug 15; 72(16):4193-203.
View in:
PubMed
Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol. 2012 Sep 01; 30(25):3127-35.
View in:
PubMed
BH3-only proteins are part of a regulatory network that control the sustained signalling of the unfolded protein response sensor IRE1a. EMBO J. 2012 May 16; 31(10):2322-35.
View in:
PubMed
BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett. 2013 May 28; 332(2):202-5.
View in:
PubMed
Who put the "A" in Atg12: autophagy or apoptosis? Mol Cell. 2011 Dec 23; 44(6):844-5.
View in:
PubMed
P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood. 2012 Feb 09; 119(6):1468-78.
View in:
PubMed
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011 Nov 25; 334(6059):1129-33.
View in:
PubMed
Targeting Bcl-2 in CLL: cui bono? Blood. 2011 Sep 29; 118(13):3453-4.
View in:
PubMed
The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance. Cell Death Dis. 2011 Jun 23; 2:e174.
View in:
PubMed
A new face of BCL-2 inhibition in CLL. Blood. 2011 Mar 10; 117(10):2750-1.
View in:
PubMed
Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes. Proc Natl Acad Sci U S A. 2010 Jul 20; 107(29):12895-900.
View in:
PubMed
Displacement of Bim by Bmf and Puma rather than increase in Bim level mediates paclitaxel-induced apoptosis in breast cancer cells. Cell Death Differ. 2010 Oct; 17(10):1624-35.
View in:
PubMed
Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood. 2010 Apr 22; 115(16):3304-13.
View in:
PubMed
The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18; 463(7283):899-905.
View in:
PubMed
BH3-only proteins and their effects on cancer. Adv Exp Med Biol. 2010; 687:49-63.
View in:
PubMed
MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts. J Cell Biol. 2009 Nov 02; 187(3):429-42.
View in:
PubMed
Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release. Hum Mol Genet. 2009 Nov 15; 18(22):4317-28.
View in:
PubMed
Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression. Blood. 2009 Sep 24; 114(13):2699-708.
View in:
PubMed
Hiding from ABT-737 in lymph nodes. Blood. 2009 Apr 30; 113(18):4132-3.
View in:
PubMed
Puma strikes Bax. J Cell Biol. 2009 Apr 20; 185(2):189-91.
View in:
PubMed
Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci. 2009 Feb 15; 122(Pt 4):437-41.
View in:
PubMed
Mimicking the BH3 domain to kill cancer cells. Oncogene. 2008 Dec; 27 Suppl 1:S149-57.
View in:
PubMed
Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res. 2008 Oct 01; 68(19):7985-94.
View in:
PubMed
BIM and other BCL-2 family proteins exhibit cross-species conservation of function between zebrafish and mammals. Cell Death Differ. 2008 Jun; 15(6):1063-72.
View in:
PubMed
Regulation of Bcl-2 family proteins by posttranslational modifications. Curr Mol Med. 2008 Mar; 8(2):102-18.
View in:
PubMed
Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer. 2008 Feb; 8(2):121-32.
View in:
PubMed
Rational design of therapeutics targeting the BCL-2 famil: Are some cancer cells primed for death but waiting for a final push?. Programmed Cell Death in Cancer Progression and Therapy. 2008; 159-176.
Rational design of therapeutics targeting the BCL-2 family: are some cancer cells primed for death but waiting for a final push? Adv Exp Med Biol. 2008; 615:159-75.
View in:
PubMed
Apoptosis Dysregulation in CLL. Chronic Lymphocytic Leukemia. 2008.
Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res. 2007 Dec 15; 67(24):11867-75.
View in:
PubMed
BH3 domains define selective inhibitory interactions with BHRF-1 and KSHV BCL-2. Cell Death Differ. 2008 Mar; 15(3):580-8.
View in:
PubMed
BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood. 2008 Feb 15; 111(4):2300-9.
View in:
PubMed
BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell. 2007 Aug; 12(2):171-85.
View in:
PubMed
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007 Jan; 117(1):112-21.
View in:
PubMed
Restoring cancer's death sentence. Cancer Cell. 2006 Nov; 10(5):343-5.
View in:
PubMed
Laying the foundations of programmed cell death. Cell Death Differ. 2006 Aug; 13(8):1245-7.
View in:
PubMed
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006 May; 9(5):351-65.
View in:
PubMed
BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastoma. Oncogene. 2006 Aug 03; 25(33):4525-33.
View in:
PubMed
Growth factor withdrawal and apoptosis: the middle game. Mol Cell. 2006 Mar 17; 21(6):728-30.
View in:
PubMed
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell. 2005 Nov; 8(5):407-19.
View in:
PubMed
Pharmacological manipulation of Bcl-2 family members to control cell death. J Clin Invest. 2005 Oct; 115(10):2648-55.
View in:
PubMed
BCL-2: found bound and drugged! Trends Mol Med. 2005 Oct; 11(10):442-4.
View in:
PubMed
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005 Jun 02; 435(7042):677-81.
View in:
PubMed
Lymphoid Neoplasms. Molecular Hematology. 2005; 105-114.
Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell. 2004 Sep; 6(3):241-9.
View in:
PubMed
Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature. 2003 Dec 11; 426(6967):671-6.
View in:
PubMed
Smallpox and smallpox vaccination. N Engl J Med. 2003 May 08; 348(19):1920-5; author reply 1920-5.
View in:
PubMed
BH3 domains as BCL-2 inhibitors: prototype cancer therapeutics. Expert Opin Biol Ther. 2003 Apr; 3(2):293-304.
View in:
PubMed
Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002 Sep; 2(3):183-92.
View in:
PubMed
Cancer, coagulation, and anticoagulation. Oncologist. 1999; 4(6):443-9.
View in:
PubMed
The importance of intramolecular ion pairing in intermediate filaments. Proc Natl Acad Sci U S A. 1995 Jan 03; 92(1):92-6.
View in:
PubMed
Genetic bases of epidermolysis bullosa simplex and epidermolytic hyperkeratosis. J Invest Dermatol. 1994 Nov; 103(5 Suppl):25S-30S.
View in:
PubMed
Disease severity correlates with position of keratin point mutations in patients with epidermolysis bullosa simplex. Proc Natl Acad Sci U S A. 1993 Apr 15; 90(8):3197-201.
View in:
PubMed
Keratin Mutations and Heritable Skin Disease. 1993.
The genetic basis of epidermolytic hyperkeratosis: a disorder of differentiation-specific epidermal keratin genes. Cell. 1992 Sep 04; 70(5):811-9.
View in:
PubMed
Do the ends justify the mean? Proline mutations at the ends of the keratin coiled-coil rod segment are more disruptive than internal mutations. J Cell Biol. 1992 Mar; 116(5):1181-95.
View in:
PubMed
Point mutations in human keratin 14 genes of epidermolysis bullosa simplex patients: genetic and functional analyses. Cell. 1991 Sep 20; 66(6):1301-11.
View in:
PubMed
Pancreas-graft immunogenicity and pretreatment with anti-class II monoclonal antibodies. Diabetes. 1989 Jan; 38 Suppl 1:104-8.
View in:
PubMed
Specificity in formation of triple-stranded nucleic acid helical complexes: studies with agarose-linked polyribonucleotide affinity columns. Biochemistry. 1988 Dec 27; 27(26):9108-12.
View in:
PubMed